Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biodelivery Sci Intl (BDSI)

Biodelivery Sci Intl (BDSI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 514,757
  • Shares Outstanding, K 89,523
  • Annual Sales, $ 55,640 K
  • Annual Income, $ -33,870 K
  • 60-Month Beta 0.43
  • Price/Sales 4.64
  • Price/Cash Flow N/A
  • Price/Book 7.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.01
  • Number of Estimates 6
  • High Estimate 0.03
  • Low Estimate -0.01
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +110.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.48 +4.56%
on 01/14/20
7.21 -20.53%
on 12/26/19
-0.69 (-10.75%)
since 12/20/19
3-Month
5.16 +11.15%
on 10/23/19
7.21 -20.53%
on 12/26/19
+0.53 (+10.19%)
since 10/22/19
52-Week
3.59 +59.61%
on 07/30/19
7.21 -20.53%
on 12/26/19
+1.63 (+39.76%)
since 01/22/19

Most Recent Stories

More News
BDSI Expects Fourth Quarter and 2019 Total Net Sales at the High End of Guidance: Reports Significantly Expanded Insurance Access for Symproic

2019 Total Company Net Sales Expected at Upper End of $105 to $110 Million

BDSI : 5.73 (-0.35%)
What Makes BioDelivery (BDSI) a New Buy Stock

BioDelivery (BDSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BDSI : 5.73 (-0.35%)
BioDelivery Sciences Appoints Kevin Ostrander as Senior Vice President of Business Development

BioDelivery Sciences International, Inc. (Nasdaq: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, announced today the...

BDSI : 5.73 (-0.35%)
Flexion's (FLXN) Stock Up on FDA Approval for Zilretta sNDA

Flexion's (FLXN) sNDA for osteoarthritis drug, Zilretta, seeking removal of confusing limitation of use label, gets FDA approval.

CHRS : 18.99 (-1.50%)
ALKS : 18.58 (+0.30%)
BDSI : 5.73 (-0.35%)
FLXN : 18.41 (+0.66%)
Are You Looking for a Top Momentum Pick? Why BioDelivery Sciences International (BDSI) is a Great Choice

Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.

BDSI : 5.73 (-0.35%)
BioDelivery Sciences Added to NASDAQ Biotechnology Index

BioDelivery Sciences International, Inc. (Nasdaq: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced it has...

IBB : 120.55 (-0.14%)
BDSI : 5.73 (-0.35%)
BioDelivery (BDSI) Up 6% Since Last Earnings Report: Can It Continue?

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BDSI : 5.73 (-0.35%)
Emmy® and Tony Award® Winning Actress Kristin Chenoweth Introduces 'This Is Pain' Campaign to Improve the Lives of Those Living with Chronic Pain

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the launch...

BDSI : 5.73 (-0.35%)
What Makes BioDelivery Sciences International (BDSI) a Strong Momentum Stock: Buy Now?

Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.

BDSI : 5.73 (-0.35%)
Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon

Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.

ANIK : 45.71 (-0.39%)
ALKS : 18.58 (+0.30%)
BDSI : 5.73 (-0.35%)
ZEAL : 37.00 (+0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade BDSI with:

Business Summary

BioDelivery Sciences International is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology designed for a potentially broad base of pharmaceuticals, vaccines and over-the-counter drugs. In general, a drug delivery technology refers to any...

See More

Key Turning Points

2nd Resistance Point 5.92
1st Resistance Point 5.82
Last Price 5.73
1st Support Level 5.67
2nd Support Level 5.62

See More

52-Week High 7.21
Fibonacci 61.8% 5.83
Last Price 5.73
Fibonacci 50% 5.40
Fibonacci 38.2% 4.97
52-Week Low 3.59

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar